423 related articles for article (PubMed ID: 32244756)
21. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
[TBL] [Abstract][Full Text] [Related]
22. A Designer Scaffold with Immune Nanoconverters for Reverting Immunosuppression and Enhancing Immune Checkpoint Blockade Therapy.
Phuengkham H; Song C; Lim YT
Adv Mater; 2019 Oct; 31(42):e1903242. PubMed ID: 31490604
[TBL] [Abstract][Full Text] [Related]
23. Cardiotoxicity from immune checkpoint inhibitors.
Michel L; Rassaf T; Totzeck M
Int J Cardiol Heart Vasc; 2019 Dec; 25():100420. PubMed ID: 31517036
[TBL] [Abstract][Full Text] [Related]
24. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
Yi M; Jiao D; Qin S; Chu Q; Wu K; Li A
Mol Cancer; 2019 Mar; 18(1):60. PubMed ID: 30925919
[TBL] [Abstract][Full Text] [Related]
26. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
Li X; Wenes M; Romero P; Huang SC; Fendt SM; Ho PC
Nat Rev Clin Oncol; 2019 Jul; 16(7):425-441. PubMed ID: 30914826
[TBL] [Abstract][Full Text] [Related]
27. T Cells and Cancer: How Metabolism Shapes Immunity.
Molon B; Calì B; Viola A
Front Immunol; 2016; 7():20. PubMed ID: 26870036
[TBL] [Abstract][Full Text] [Related]
28. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
Huang L; Xu H; Peng G
Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
[TBL] [Abstract][Full Text] [Related]
29. Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges.
Pacella I; Piconese S
Front Immunol; 2019; 10():1889. PubMed ID: 31507585
[TBL] [Abstract][Full Text] [Related]
30. Intrinsic and Tumor Microenvironment-Induced Metabolism Adaptations of T Cells and Impact on Their Differentiation and Function.
Kouidhi S; Noman MZ; Kieda C; Elgaaied AB; Chouaib S
Front Immunol; 2016; 7():114. PubMed ID: 27066006
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.
Knaus HA; Kanakry CG; Luznik L; Gojo I
Curr Drug Targets; 2017; 18(3):315-331. PubMed ID: 25981611
[TBL] [Abstract][Full Text] [Related]
32. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Giannone G; Ghisoni E; Genta S; Scotto G; Tuninetti V; Turinetto M; Valabrega G
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575899
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Adachi K; Tamada K
Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations.
Augustin RC; Delgoffe GM; Najjar YG
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348579
[TBL] [Abstract][Full Text] [Related]
36. Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy.
Bahrambeigi S; Molaparast M; Sohrabi F; Seifi L; Faraji A; Fani S; Shafiei-Irannejad V
Immunol Lett; 2020 Apr; 220():32-37. PubMed ID: 31982460
[TBL] [Abstract][Full Text] [Related]
37. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
[TBL] [Abstract][Full Text] [Related]
38. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
39. Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting.
Yu YR; Ho PC
Clin Exp Immunol; 2019 Aug; 197(2):153-160. PubMed ID: 30873592
[TBL] [Abstract][Full Text] [Related]
40. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
